



PRESS RELEASE

SOL Group continues along the path of strategic investments in the home care sector, in which it operates with VIVISOL Companies.

VIVISOL, through AIRSOL S.r.l., acquires a minority stake in the German SOMNOMEDICS GmbH, a leading operator in the sleep diagnostics sector at international level.

SOL Group - a multinational dealing not only in the technical, industrial and medicinal gases sector, but also in the home care sector through Companies identified by the "**VIVISOL**" brand - announces that the company AIRSOL S.r.l. - entirely controlled by SOL S.p.A - has signed a new strategic partnership in the home care sector, through the acquisition of **15% of the German company SOMNOmedics GmbH, global leader in the field of sleep diagnostics.**

Founded in 2000 by Dr. Gert Kuechler, SOMNOmedics has developed strongly over the years, going from a start up to becoming a market leader in the sleep apnoea diagnostics sector, thanks to constant innovation and the excellence of its products.

In 2022 financial year, SOMNOmedics achieved a turnover of approximately **20 million Euros**, with a staff of **140 people** and activities in over 45 Countries around the world.

The operation aims to strengthen the international positioning in the sleep medicine sector, one of Vivisol's main business areas and with a high potential for future development. To date, Vivisol offers home diagnosis and therapy services for sleep-related breathing disorders in all 18 Countries in which it operates.

Claudio Garbellini, Deputy General Manager of the Group and responsible for Home Care activities, commented: *"The close cooperation between VIVISOL and SOMNOmedics dates back several years, and the decision to become its shareholders was a natural consequence. This partnership confirms our desire to continue growing in the sleep apnoea disorders sector."*

Aldo Fumagalli Romario, Chairman and CEO of SOL Group, commented: *"We are very pleased with this partnership with SOMNOmedics, and in particular with Dr. Gert Kuechler, innovative entrepreneur and inspirer for the company. We are confident that the quality of SOMNOmedics' technological solutions and the solidity of its future plans will support our mission as a Home Care therapy service provider, i.e., to give our patients the opportunity to live their lives in their homes and not in hospitals."*

Gert Kuechler, founder and CEO of SOMNOmedics, commented: *"With this important step, we will strengthen our strategic cooperation which has already been successful for some time in more than five European Countries, with VIVISOL also as the company's first shareholder partner since it changed from being a GmbH to a joint-stock company. In the sleep apnoea market, the strong interaction between diagnostics and therapy is clearly a benefit for physicians, patients and certainly also for both our Companies. VIVISOL is a family company, like SOMNOmedics, and both are inspired by the same spirit."*

SOL is a multinational group that operates in Europe, India, Turkey, Morocco, Brazil, China, Ecuador and Peru, in two different main sectors: production, applied research and sale of technical, pure and medicinal gases (Technical Gases Division) and Home Medical Assistance (Home Care Division - VIVISOL), with over €1.378 million turnover in 2022, and over 5,750 employees.



B&P
Barabino & Partners

for



VIVISOL
Home Care Services

SOMNOmedics is a leading company in the field of sleep apnoea diagnostics, with global activities and operations in over 45 Countries around the world. Through new products, developed using proprietary knowledge and experience, SOMNOmedics operates with innovations also in other sectors of medical diagnostics, such as cardiology, anesthesiology, neurology, and intensive care. In recent years, SOMNOmedics is positioning as a global supplier of medical devices for diagnostics, as well as being a specialist in sleep diagnostics.

Contacts: Barabino & Partners
Marina Riva
Ph. +39 02 72 02 35 35
m.riva@barabino.it

Monza, 9th October, 2023